belumosudil mesilate: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
belumosudil mesilate: clinical details
Prescribing considerations
- Initiate and supervise treatment through clinicians experienced in chronic graft-versus-host disease.
- Confirm the licensed age and previous systemic-treatment criteria.
- Review pregnancy status, contraception, hepatic and renal function, and interacting medicines before initiation.
- Strong CYP3A4 inducers and gastric acid suppression can materially reduce exposure.
- Use is not recommended in moderate or severe hepatic impairment without liver graft-versus-host disease. Use cautiously in severe renal impairment or dialysis because evidence is lacking.
Contraindications and cautions
- Pregnancy
- Hypersensitivity to belumosudil mesilate or any excipient
Monitoring
- Obtain a full blood count and liver-function tests before initiation.
- Monitor liver-function tests at least monthly during treatment.
- Assess promptly for hepatotoxicity, infection, cytopenias and other clinically significant adverse reactions.
Clinical pharmacology
Belumosudil is a selective ROCK2 inhibitor affecting immune and fibrotic signalling. Exposure increases with food. It is predominantly metabolised through CYP3A4, is highly protein-bound and is eliminated mainly in faeces.
Formulation and product differences
- The pale-yellow film-coated tablet must not be broken, crushed or chewed.
- It is essentially sodium-free.
- It is supplied in a moisture-protective bottle with a desiccant; retain the original packaging and close the cap securely.
belumosudil mesilate preparations and strengths
Tablet
Route: Oral
Strengths: 200 mg
belumosudil mesilate interactions
A full interaction review is important before starting or stopping any prescribed, over-the-counter or herbal product.
Strong CYP3A4 inducers, such as rifampicin
They can substantially reduce belumosudil exposure, so specialist review is required.
Proton-pump inhibitors, including omeprazole and rabeprazole
They can markedly reduce belumosudil absorption and require specialist management.
Other gastric acid-reducing treatments
They may reduce belumosudil exposure. Confirm management with the specialist team.
Sources
These sources were used to prepare and review this medicine page.
iatroX CPD
Keep a note for CPD
Save a private reflection with this source attached. Your first is free.
Record learning (opens in a new tab)Prepared and reviewed by the iatroX editorial team.